JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA - News) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the company’s Abbreviated New Drug Application (ANDA) to market its Generic version of GlaxoSmithKline’s cardiovascular agent Coreg® (Carvedilol) Tablets, 3.125 mg, 6.25 mg, 12.5 mg and 25 mg. Shipment of this product will begin immediately.
